Detalhe da pesquisa
1.
A novel cDNA-uPA/SCID/Rag2-/- /Jak3-/- mouse model for hepatitis virus infection and reconstruction of human immune system.
J Viral Hepat
; 30(3): 262-272, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36575861
2.
The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma.
Int J Cancer
; 151(12): 2278-2290, 2022 Dec 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36054900
3.
CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients.
J Viral Hepat
; 25(12): 1555-1564, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29998562
4.
Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
J Med Virol
; 89(11): 1963-1972, 2017 11.
Artigo
Inglês
| MEDLINE | ID: mdl-28657143
5.
Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma.
Cancers (Basel)
; 16(7)2024 Mar 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38611007
6.
Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment.
Cancers (Basel)
; 15(17)2023 Aug 24.
Artigo
Inglês
| MEDLINE | ID: mdl-37686510
7.
A case with life-threatening secondary sclerosing cholangitis caused by nivolumab.
Clin J Gastroenterol
; 14(1): 283-287, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-33200345
8.
Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection.
Clin J Gastroenterol
; 13(6): 1233-1238, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32656649
9.
Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.
Clin J Gastroenterol
; 13(2): 267-270, 2020 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-31463795
10.
PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.
J Gastroenterol
; 55(12): 1162-1170, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-33057914
11.
Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma.
Clin Transl Gastroenterol
; 11(5): e00179, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32677805
12.
Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice.
J Gastroenterol
; 54(7): 650-659, 2019 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-30790056
13.
Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.
J Gastroenterol
; 53(4): 548-556, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-28815329
14.
Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.
J Gastroenterol
; 53(2): 269-280, 2018 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-28741270
15.
The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients.
J Gastroenterol
; 52(3): 366-375, 2017 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-27422771
16.
ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
J Gastroenterol
; 52(6): 746-753, 2017 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-27822709
17.
Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir.
J Gastroenterol
; 52(1): 125-126, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-27541041